Clinical Advances in the

Management of Lung Cancer

CME Activities

Immunotherapy for Early-Stage Resectable NSCLC: What Do You Know?

Medscape Education, June 2023

Do you know the latest data on immune checkpoint inhibitors in early-stage non-small cell lung cancer (NSCLC)?

0.25 CME

0.25 ABIM MOC
Managing Early-Stage Resectable Non-Small Cell Lung Cancer: Through the Eyes of the Patient and the Care Team

Medscape Education, June 2023

How prepared are you to talk about available perioperative immunotherapies for early-stage resectable non-small cell lung cancer (NSCLC) with your patients?

0.50 CME

0.50 ABIM MOC
Advancing Outcomes for ALK-Positive Non-Small Cell Lung Cancer: How Might Management Continue to Evolve?

Medscape Education, June 2023

Are you up to date on the management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and the latest developments for ALK inhibitors in the early-stage setting?

0.50 CME

0.50 ABIM MOC
Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives

Medscape Education, May 2023

The complexity of treatment has increased dramatically; how effectively are you communicating with your patients?

0.50 CME

0.50 ABIM MOC
Early-Stage Resectable Non-Small Cell Lung Cancer: Navigating a Changing Treatment Landscape

Medscape Education, January 2023

Did you know that there are now promising perioperative immunotherapies available for your patients with early-stage NSCLC?

0.50 CME
RET Inhibitors for RET-Altered Non-Small Cell Lung Cancer: Identification, Treatment, and Practicalities

Medscape Education, November 2022

Did you know that RET fusions have been detected in 1% to 2% of all lung cancers and can be treated with available targeted therapies?

0.50 CME
Frontline Management of Extensive-Stage Small Cell Lung Cancer: Putting Your Skills to the Test

Medscape Education, September 2023

How would you treat these patients with extensive-stage small cell lung cancer?

1.00 CME | ABIM MOC

Advances in Lung Cancer Management

Are you staying up to date on the innovations in lung cancer management?

Resources

Downloadable Slide Kit

Clinical Advances in the Management of Lung Cancer

Clinical Articles

Steering Committee

Solange Peters, MD, PhD

Steering Committee Chair

Professor of Oncology
Medical Oncology Chair
Lausanne University Hospital
Lausanne, Switzerland

Bio Video

Enriqueta Felip, MD, PhD

Steering Committee Member

Medical Oncologist
Head, Thoracic Malignancies
Vall d'Hebron University Hospital
Barcelona, Spain

Bio Video

Eric Lim, MBChB, MD, MSc

Steering Committee Member

Consultant Thoracic Surgeon
Royal Brompton Hospital
Professor of Thoracic Surgery
Imperial College London
Royal Brompton Hospital
London, United Kingdom

Bio Video

Stephen Liu, MD

Steering Committee Member

Associate Professor of Medicine
Director of Thoracic Oncology
Director of Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC, United States

Bio Video

Luis G. Paz-Ares, MD, PhD

Steering Committee Member

Head of the H12O-CNIO Lung Cancer Clinical Research Unit
Spanish National Cancer Research Centre (CNIO)
Universidad Complutense
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Madrid, Spain

Bio Video

Martin Reck, MD

Steering Committee Member

Professor of Medicine
Department of Thoracic Oncology
LungenClinic Großhansdorf
Großhansdorf, Germany

Bio Video

Steering Committee

Solange Peters, MD, PhD

Steering Committee Chair

Has the following relevant financial relationships:

Consultant or advisor for: AbbVie; Amgen; Arcus; AstraZeneca; Bayer; Beigene; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim; Bristol Myers Squibb; Clovis; Daiichi Sankyo; Debiopharm; Eli Lilly and Company; F-Star; Fishawack; Foundation Medicine; Genentech; Genzyme; Gilead; GlaxoSmithKline; Illumina; Imedex; IQVIA; Incyte; iTeos; Janssen; Merck Sharp & Dohme; Merck Serono; Merrimack; Novartis; Novocure; PER; Pfizer; PharmaMar; Phosplatin Therapeutics; Regeneron; Roche; RTP; Sanofi; Seagen Inc.; Takeda; Vaccibody

Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Foundation Medicine; Genentech; Illumina; Imedex; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Roche; RTP; Sanofi; Takeda

Research funding from: Amgen; AstraZeneca; Beigene; Bristol Myers Squibb; Genentech; GlaxoSmithKline; Merck Sharp & Dohme; Roche

Enriqueta Felip, MD, PhD

Steering Committee Member

Has the following relevant financial relationships:

Consultant or advisor for: AbbVie; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi Sankyo; Eli Lilly and Company; F. Hoffman La Roche; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda

Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; F. Hoffmann La Roche; Janssen; Medical Trends; Merck; Merck Sharp & Dohme; Pfizer; Sanofi; Takeda; Touch Oncology

Research funding from: Fundacion Merck Salud; Merck Healthcare KGAa

Other: Independent member of the board of Grifols

Eric Lim, MBChB, MD, MSc

Steering Committee Member

Has the following relevant financial relationships:

Consultant or advisor for: AstraZeneca; Beigene; Bristol Myers Squibb; Covidien; Ethicon; Johnson and Johnson; Medela; Medtronic; Roche

Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb; Covidien; Ethicon; Johnson and Johnson; Medela; Medtronic; Roche

Research funding from: Guardant Health; Medela; Medtronic

Contracted researcher for: Clearbridge Biomedics; Medela; Screencell

Patent beneficiary of: Imperial Innovations - P52435GB (Microfluidic staining), P57988GB (blood based COLD-PCR primer development)

Ownership interest: Healthcare Companion Ltd

Other: Receipt of unrestricted funds for the development of My Cancer Companion patient education app from: AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly and Company Oncology; Takeda Oncology

Stephen Liu, MD

Steering Committee Member

Has the following relevant financial relationships:

Consultant or advisor for: Amgen; AstraZeneca; Bayer; Beigene; Blueprint; Boehringer Ingelheim; Bristol Myers Squibb; Catalyst; Daiichi Sankyo; Eisai; Elevation Oncology; Genentech; Gilead; Guardant Health; Janssen; Jazz Pharmaceuticals; Merck; Merck Sharp and Dohme; Novartis; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics

Research funding from: Alkermes; Bayer; Blueprint; Bristol Myers Squibb; Elevation Oncology; Genentech; Gilead; Merck; Merus; Nuvalent; Pfizer; RAPT; Turning Point Therapeutics

Luis G. Paz-Ares, MD, PhD

Steering Committee Member

Has the following relevant financial relationships:

Consultant or advisor for: Amgen; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Daiichi Sankyo; Eli Lilly and Company; GlaxoSmithKline; Janssen; Merck Serono; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Pharmamar; Roche; Sanofi; Takeda

Speaker or member of speakers bureau for: Amgen; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Eli Lilly and Company; Daiichi Sankyo; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Pharmamar; Roche; Sanofi; Servier; Takeda

Martin Reck, MD

Steering Committee Member

Has no relevant financial relationships.